Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

This study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) (CDR of 0.5; age 65-85) in a randomized clinical trial of 8 weeks of t-PBM vs. sham. At baseline, all subjects will complete initial neuropsychological testing. To elucidate mechanisms of action of t-PBM, prior to treatment, subjects will undergo neuroimaging related to critical features of AD: tau 18F MK-6240 load (PET), measures of brain bioenergetics (31P-MRS), and functional connectivity (rs-fMRI). Subjects will then be randomized to t-PBM/sham and will undergo target engagement testing (first t-PBM session performed during fMRI to detect BOLD changes with t-PBM). aMCI subjects will then complete t-PBM/sham treatments in two participating centers (NYU/NKI acting as a single center, and MGH), ~10 min per day, 3 days per week, for 8 weeks. t-PBM will be administered via pulsed, 808nm wavelength laser delivery to the forehead bilaterally (at standard EEG electrode positions F4, F3).

Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

Recruitment

Summary

Participation Requirements

Description

Tracking Information